The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But GLP-1s can be an effective reinforcement of diet and exercise.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

A new study has found that a diabetes medicine called tirzepatide can help people lower their blood sugar and lose weight ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...